The Hedge Fund Winners From Immunovant’s Rise

The biopharma stock’s increase was a much needed boost to life sciences funds, which have made only slight gains this year.


Illustration by II

Thanks, we needed that.

This is no doubt the reaction among a number of hedge fund investors who have direct or indirect investments in Immunovant, a clinical-stage immunology company whose stock price almost doubled on Tuesday after reporting encouraging news about a drug in development.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.